GW Pharmaceuticals PLC (GWPH) Trading Down 3.8% After Analyst Downgrade
GW Pharmaceuticals PLC (NASDAQ:GWPH)’s share price was down 3.8% during trading on Monday after ValuEngine downgraded the stock from a hold rating to a sell rating. The company traded as low as $96.42 and last traded at $97.62. Approximately 858,878 shares changed hands during mid-day trading, an increase of 192% from the average daily volume of 293,734 shares. The stock had previously closed at $101.49.
Other equities analysts have also issued reports about the stock. BidaskClub upgraded shares of GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Zacks Investment Research raised shares of GW Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $119.00 price target for the company in a report on Monday, July 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $208.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Monday. Cowen and Company reaffirmed an “outperform” rating and set a $165.00 price objective on shares of GW Pharmaceuticals PLC in a report on Monday. Finally, Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Thursday, June 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $149.83.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Alliancebernstein L.P. boosted its holdings in shares of GW Pharmaceuticals PLC by 4.6% in the first quarter. Alliancebernstein L.P. now owns 286,475 shares of the biopharmaceutical company’s stock valued at $34,646,000 after buying an additional 12,519 shares during the period. Blair William & Co. IL bought a new stake in shares of GW Pharmaceuticals PLC during the first quarter worth $207,000. Victory Capital Management Inc. increased its position in shares of GW Pharmaceuticals PLC by 9.2% during the second quarter. Victory Capital Management Inc. now owns 308,945 shares of the biopharmaceutical company’s stock worth $30,971,000 after acquiring an additional 25,920 shares in the last quarter. Eqis Capital Management Inc. raised its holdings in shares of GW Pharmaceuticals PLC by 23.3% during the second quarter. Eqis Capital Management Inc. now owns 2,899 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 547 shares during the period. Finally, HighTower Advisors LLC raised its holdings in shares of GW Pharmaceuticals PLC by 10.3% during the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 191 shares during the period. 75.06% of the stock is currently owned by hedge funds and other institutional investors.
The company’s market cap is $2.49 billion. The company has a 50 day moving average price of $105.31 and a 200 day moving average price of $108.39.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last issued its earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The firm had revenue of $3.14 million during the quarter, compared to the consensus estimate of $2.10 million. During the same period in the previous year, the firm earned ($0.05) earnings per share. Equities research analysts predict that GW Pharmaceuticals PLC will post ($5.94) EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/03/gw-pharmaceuticals-plc-gwph-trading-down-3-8-after-analyst-downgrade.html.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.